Market Research Report
Investigation Report on China's Docetaxel Market 2021-2025
|Published by||China Research and Intelligence||Product code||1009416|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|Investigation Report on China's Docetaxel Market 2021-2025|
|Published: June 4, 2021||Content info: 50 Pages||
Docetaxel, sold under the brand name Taxotere, is a paclitaxel anti-tumor drug used for the treatment of locally advanced or metastatic non-small cell lung cancer. Docetaxel injection was first developed and produced by the French company Rhone Planck Lean (later renamed Aventis, also known as Sanofi-Aventis). It was first approved for marketing by the European Union in 1995 and approved in China in 1996. By 2020, there are several manufacturers in the Chinese Docetaxel market.
According to CRI's market research, the sales value of Docetaxel in the Chinese market remained constant from 2016 to 2019. Due to the impact of the COVID-19 epidemic on China's hospital's overall diagnosis and treatment services, the sales value of Docetaxel in the Chinese market decreased to CNY1.112 billion in 2020, a year-on-year decrease of 16.79%. The CAGR of the sales value of Docetaxel in the Chinese market from 2016 to 2020 was -3.86%.
CRI expects that with the alleviation of the COVID-19 epidemic, sales of Docetaxel will have a restorative growth from 2021 to 2025. In addition, 4.57 million new cancer cases were diagnosed in China in 2020, and the overall cancer incidence increased by about 3.9% annually. Therefore, the sales volume of Docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer will increase with the increase of colon cancer patients and there is room for sales to rise. At the same time, compared with similar drugs, Docetaxel is safer and more effective, the sales volume will grow in the future.